LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

Strona główna・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorHealthcare

26.13 -2.35

Buy Sell

Overview

Share price change

24h

Current

Min

25.18

Max

26.51

Key metrics
By Trading Economics
Income	-10M -67M
EPS	-1.01
Profit margin	-7,753.425
Employees	186
EBITDA	-9.8M -73M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+104.99% upside

Market Stats
By TradingEconomics
Market Cap	307M 1.8B
Previous open	28.48
Previous close	26.13

News Sentiment

By Acuity

50%

152 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 gru 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 gru 2025, 14:57 UTC

Acquisitions, Mergers, Takeovers

Accenture to Acquire Cabel Industry from Fibonacci Group

25 gru 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 gru 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 gru 2025, 00:20 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 gru 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 gru 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 gru 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 gru 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

24 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 gru 2025, 17:08 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 gru 2025, 16:53 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 gru 2025, 16:31 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 gru 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 gru 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 gru 2025, 15:33 UTC

Acquisitions, Mergers, Takeovers

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 gru 2025, 15:30 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 15:19 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 14:49 UTC

Acquisitions, Mergers, Takeovers

Mexico's Ollamani Sells Stake in Azteca Stadium

24 gru 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 gru 2025, 14:08 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 gru 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 gru 2025, 12:59 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 gru 2025, 12:51 UTC

Acquisitions, Mergers, Takeovers

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

104.99% upside

12 Months Forecast

Average 55 USD 104.99%

High 90 USD

Low 24 USD

Based on 10 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

152 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.